Paul Meeks of Freedom Capital Markets says he is "a little bit worried" about Cerebras (CBRS) after the move the stock has made today ahead of its earnings report.
"I definitely would not buy this ahead of earnings," he tells
@NPetallides, adding that it's "risky and overvalued." He has the lowest price target on the Street for $CBRS at $209.
For more market news, tune in at: